Library · Metabolic & weight · Chronic weight management in genetic obesity (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome)
Setmelanotide
IMCIVREE
A first-in-class MC4R agonist, FDA-approved in 2020 for chronic weight management in adults and children six and older with obesity caused by POMC, PCSK1, or LEPR deficiency. This cyclic octapeptide crosses the blood-brain barrier to restore hypothalamic appetite control.
Research score 85/100. Reference only, not a dose.
- Weight Loss
- Appetite Suppression
- US status
- Prescription Only
- Approval
- FDA Approved (2020)
- Evidence
- Demonstrated significant weight loss in Phase 3 trials for patients with POMC and LEPR deficiency
- Research score
- 85 / 100
- Indication
- Genetic obesity (POMC, PCSK1, or LEPR deficiency)
- Origin
- France (Ipsen), United States (Rhythm Pharmaceuticals)
- Source category
- Metabolism & Weight Management
- Status group
- Approved / prescription
Mechanism
Activates melanocortin receptors MC4R, MC3R, and MC1R in the hypothalamus, restoring signaling in the melanocortin pathway that governs appetite and energy use.
Safety file
Common effects include injection-site reactions and hyperpigmentation; serious risks include depression, suicidal thoughts, and sexual side effects.
- Injection site reactions
- Skin hyperpigmentation
- Headache
- Nausea
- Diarrhea
- Depression